Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atazanavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | CTSD | P07339 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CTSE | P14091 | 1/20 | 0.41 |
| ▸ | PGC | P20142 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atazanavir SCHEMBL41697 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL9975220 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL825777 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL1559640 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL1396072 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629941 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL21565117 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629937 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL22847477 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL41696 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230288402-A1 | MOLECULES TARGETING RIBOSOMAL PROTEIN RPL35/UL29 FOR USE IN THE TREATMENT OF DISEASES, IN PARTICULAR EPIDERMOLYSIS BULLOSA (EB) | KBHB Consult GmbH (AT) | 2023-09-14 | — | — | US | disclosed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230173079-A1 | Conjugate Molecules | DIVERSE BIOTECH, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230148179-A1 | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11318119-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11078208-B1 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11052087-B2 | Anti-HIV compounds | GILEAD SCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| US-10294234-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20190125875-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | BRISTOL MYERS SQUIBB CO (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2956439-B1 | PROCESS FOR PREPARING ATAZANAVIR SULPHATE | CIPLA LTD (IN) | 2019-01-09 | — | — | EP | disclosed |
| US-20180071270-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-9890121-B2 | Process for preparing atazanavir sulphate | CIPLA LIMITED (IN) | 2018-02-13 | — | — | US | disclosed |
| US-20180021436-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | BRISTOL MYERS SQUIBB CO (US) | 2018-01-25 | — | — | US | disclosed |
| US-20090270499-A1 | Process for Synthesizing Atazanavir | OXYRANE (UK) LIMITED (UK) | 2009-10-29 | — | — | US | disclosed |
| US-20090270499-A1 | Process for Synthesizing Atazanavir | OXYRANE (UK) LIMITED (UK) | 2009-10-29 | — | — | US | disclosed |
| WO-2009130534-A1 | PROCESS FOR SYNTHESIZING ATAZANAVIR | OXYRANE (PTY) LTD. (ZA) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | UGT1A1 1691/4885MLNR 4335/4885NR1I2 3135/4885 |
| US-11052087-B2 | Anti-HIV compounds | CCR5, CD4, NFATC1 | UGT1A1 624/4885MLNR 4126/4885NR1I2 3064/4885 |
| US-20180071270-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885MLNR 1210/4885NR1I2 3899/4885 |
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | UGT1A1 1587/4885MLNR 4096/4885NR1I2 3200/4885 |
| US-20190125875-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | ACIN1, SAMHD1, ARSA | UGT1A1 2092/4885MLNR 2550/4885NR1I2 3993/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | UGT1A1 2264/4885MLNR 4024/4885NR1I2 3134/4885 |
| US-11078208-B1 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | UGT1A1 1691/4885MLNR 4335/4885NR1I2 3135/4885 |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | UGT1A1 4630/4885MLNR 1389/4885NR1I2 1985/4885 |
| US-11318119-B2 | HIV protease inhibitors | ACE, PRSS1, TMPRSS2 | UGT1A1 3260/4885MLNR 4179/4885NR1I2 4409/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | UGT1A1 4517/4885MLNR 1970/4885NR1I2 3465/4885 |
| US-20230148179-A1 | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF | ACE2, ACE, SARS1 | UGT1A1 2487/4885MLNR 2651/4885NR1I2 862/4885 |
| US-20230173079-A1 | Conjugate Molecules | CNR2, CNR1, MAG | UGT1A1 345/4885MLNR 461/4885NR1I2 2269/4885 |
| US-20180021436-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | ACIN1, SAMHD1, ARSA | UGT1A1 2092/4885MLNR 2550/4885NR1I2 3993/4885 |
| US-10294234-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | UGT1A1 1691/4885MLNR 4335/4885NR1I2 3135/4885 |
| US-20090270499-A1 | Process for Synthesizing Atazanavir | SAMHD1, TYMS, COASY | UGT1A1 309/4885MLNR 3692/4885NR1I2 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.